Mersana Announces First Patient Dosed with XMT-1536 in Phase 1 Study in Patients with NaPi2b-Expressing Tumors
Trial to Study Patients in Ovarian, NSCLC and Other Cancers XMT-1536 is Second Dolaflexin Antibody Drug Conjugate to Enter Clinical Trials CAMBRIDGE, Mass., Dec. 12, 2017 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage …